• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

    3/25/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    Stephen MacMillan to retire from the Board

    SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company's upcoming annual meeting of shareholders.

    "I'm honored to accept this role at Illumina, a company at the forefront of our rapidly evolving industry, whose groundbreaking innovations continue to transform patient opportunities and shape the field of genomics," Dr. Gottlieb said. "I extend our gratitude to Steve for his dedication and commitment to Illumina, and I look forward to continuing to collaborate with the board and management team to advance the company's mission and to drive profitable growth. We also welcome to the board Keith Meister, who brings experience as an investor in the field of genomics along with a strong record of supporting value creation for shareholders."

    Mr. MacMillan commented, "I am pleased with what Illumina has accomplished in advancing genomics and fostering groundbreaking innovations that have shaped our field, and I am grateful to the board for entrusting me with the opportunity to contribute to this remarkable company. I leave with great confidence in the board and the management team. Their collective vision, leadership, and deep commitment to scientific progress give me every reason to believe they'll continue—and indeed amplify—the transformative work we have set in motion."

    "I look forward to working with Illumina's Board and strong management team," Mr. Meister said. "Illumina has the right strategy to drive the expansion of its role in helping to shape the field of genomics and expand the application of these technologies for patient care, and I'm confident in Illumina's ability to accelerate revenue growth and deliver value for shareholders."

    About Scott Gottlieb, MD

    Scott Gottlieb was appointed to Illumina's Board in February 2020. Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration from 2017 to 2019. He is currently a Partner at the venture capital firm New Enterprise Associates and a Senior Fellow at the American Enterprise Institute for Public Policy Research. He serves as a director of the publicly traded companies Pfizer, Inc. and TempusAI, and is a member of the executive committee of the board of the Mount Sinai Medical System. Dr. Gottlieb is an elected member of the National Academy of Medicine.

    About Keith Meister

    Keith Meister is Managing Partner and Chief Investment Officer of Corvex Management LP, which he founded in December 2010. Mr. Meister currently serves on the boards of directors for MGM Resorts, GeneDx and Vestis. He is Chairman of the board of directors of the Harlem Children's Zone and a member of the board of trustees for the American Museum of Natural History.

    About Illumina

    Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

    Contacts

    Investors:

    Salli Schwartz

    858-291-6421

    IR@illumina.com

    Media:

    Samantha Beal

    PR@illumina.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/illumina-board-of-directors-elects-dr-scott-gottlieb-chair-keith-meister-to-join-board-of-directors-302410365.html

    SOURCE Illumina, Inc.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    5/15/2026$170.00Outperform
    RBC Capital Mkts
    5/14/2026$155.00Neutral → Outperform
    Daiwa Securities
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    More analyst ratings

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts resumed coverage on Illumina with a new price target

    RBC Capital Mkts resumed coverage of Illumina with a rating of Outperform and set a new price target of $170.00

    5/15/26 8:29:06 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Illumina from Neutral to Outperform and set a new price target of $155.00

    5/14/26 8:02:15 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/4/26 4:11:07 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/1/26 6:04:21 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/1/26 4:30:24 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights

    Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis DRAGEN™ pipelines optimized for IDT custom hybrid capture panels enable accurate, efficient, variant detection The DRAGEN Somatic for IDT Custom Panels feature a new, low-quality FFPE mode to analyze challenging samples Integrated DNA Technologies (IDT), a Danaher company and global leader in genomics, today announced a strategic collaboration with Illumina, Inc. (NASDAQ:ILMN) to enable a DRAGEN™ secondary analysis pipeline for IDT xGen™ FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an

    6/1/26 8:58:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

    Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panelsSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to acc

    5/28/26 12:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

    An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatmentSolution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD marketSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer

    5/28/26 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    SEC Filings

    View All

    Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    5/26/26 5:28:17 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SD filed by Illumina Inc.

    SD - ILLUMINA, INC. (0001110803) (Filer)

    5/19/26 4:16:55 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    4/30/26 4:09:12 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results:Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%)GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases"Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Offic

    4/30/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

    Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:

    2/5/26 4:06:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina Appoints Dr. Eric Green as Chief Medical Officer

    Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO  SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di

    1/8/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components